A trial is research, not a guaranteed treatment offer
Clinical trials are designed to answer research questions. NIH explains that participation may not provide a direct benefit and that some participants may receive a comparison treatment or placebo. Interest in an emerging GLP-1 medicine is a reasonable reason to learn more, but it does not guarantee access to that medicine or a particular result. Start by understanding the study’s purpose.[1]
Confirm the official study and research site
Use an official study listing and contact the research site through its published details. Ask whether recruitment is open and which location is enrolling. A seller using the words research or clinical grade is not thereby operating a clinical trial. The site should be able to explain the protocol, responsible investigators and screening process rather than simply offer a product for purchase.
Eligibility is part of the scientific design
NIH describes inclusion and exclusion criteria that may involve age, medical history, previous treatment and other characteristics. These criteria help define the question and protect participants. Do not conceal medicines or health information to qualify. If a study is not appropriate, ask the research team whether it can point to another legitimate study or return to the treating clinician to discuss current care.[1]
Ask what randomization means for you
Find out the possible study groups, how assignment occurs and whether you or the team will know the assignment. Ask what happens if symptoms change and whether usual care continues. These details affect the experience of participation and should be clear before consent. Do not assume that joining a trial advertised with a drug name means every participant receives that drug. For the evidence terms, read how to read GLP-1 research.
Understand the time and travel commitment
Ask about visit frequency, tests, diaries, remote tasks and the total planned duration. NIH’s participation questions include these practical details because research can require more time than ordinary treatment. Consider whether travel, work or caregiving obligations make the schedule feasible. A missed visit is not just an inconvenience if it limits the team’s ability to monitor a participant or collect the planned evidence.[2]
Separate costs, reimbursement and compensation
Ask which study-related services are paid for, which ordinary-care costs remain your responsibility and whether travel reimbursement or compensation is available. Get the explanation in writing. These are different categories, and a headline advertising compensation may not describe the full financial picture. Do not assume that all healthcare during the trial or after it ends will be covered.[2]
Consent should leave room for questions
Read the consent information and ask about risks, privacy, whom to contact and what happens if you want to leave. NIH describes informed consent as a process for understanding participation rather than a guarantee of benefit. Take the time needed to discuss it with the study team and your own clinician. If the explanation is unclear, ask again before deciding.[1]
Plan the handoff after research ends
Ask how the trial communicates results, what happens when the intervention ends and who will manage ongoing care. An investigational medicine may not be available afterward. The transition deserves attention before enrollment, particularly if a current care plan is affected. This is one reason development status and trial evidence should remain separate from commercial availability claims. Related reading: retatrutide trial and approval status.
Continue your research
Sources & scope
Sources checked October 13, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
Prices and terms can change. Confirm your specific offer directly with the provider.